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Apoptosis is essential for cellular homeostasis and is also a pathologic feature of various 
diseases.  The balance between Bcl-2 family proteins determines whether a cell will live or die.  
Bax, a member of the BCL-2 family proteins, is a pro-apoptotic protein that exists in both a 
soluble, cytoplasmic form and a membrane-bound form.  Upon apoptotic stimuli, Bax undergoes 
a conformational change and translocates to the mitochondria, initiating apoptotic events.  
However, little is known about whether Bax is involved in the regulation of mitochondrial 
function under non-apoptotic conditions, and how Bax binds to mitochondria to exert its activity.  
Here, we investigate the role of Bax in the regulation of mitochondrial function under non-
apoptotic conditions and explore the molecular mechanisms for Bax binding mitochondria under 
apoptotic stimuli. 
Using Bax-containing and Bax-deficient (Bax
-/-
) HCT-116 cells, we examined Bax 
cellular localization and its effects on mitochondria bioenergetics, and also tested whether over-
expression of full-length Bax in Bax
-/- 
cells would recover mitochondrial metabolic activity.  To 
determine the effects of Bax localization upon mitochondrial function, we measured citrate 
synthase activity and ATP generation.  We showed that Bax localized to the outer and inner 
mitochondrial membranes in non-apoptotic cells, enabling the activity of citrate synthase and the 
generation of ATP.  Loss of Bax led to impairment of respiring mitochondria morphology and 
reduced oxidative capacity, all of which was restored by expression of full-length or C-terminal-
deleted Bax.  These findings indicate that under non-apoptotic conditions, the constitutive 
expression of Bax is necessary for mitochondrial bioenergetics.  
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To determine the molecular mechanisms for Bax binding mitochondria under apoptotic 
stimuli, we previously performed in silico-mutagenesis and predicted that Lysines 189/190, in 
the C-terminal α9 helix, could regulate Bax binding to mitochondria.  We demonstrated here that 
these lysines are the structural elements responsible for controlling how Bax interacts with the 
mitochondrial membrane.  Expression of full-length Bax led to mitochondrial translocation and 
apoptosis, whereas deletion of the α9 helix resulted in cytosolic retention and dramatically 
reduced cell death.  Mutation of the two lysine residues changed how Bax bound to 
mitochondrial membranes.  We replicated the results achieved with full-length Bax by attaching 
the α9 helix of Bax to GFP or to a regulatory element, the degradation domain (DD), and 
induced apoptosis upon expression in cells.  We demonstrated that the α9 helix alone promoted 
the mitochondrial translocation of Bax and increased apoptosis.  These results indicate that the 
C-terminal α9 helix could be further studied for use in cancer therapies.  
Overall, we have demonstrated that the constitutive expression of the inactive form of 
Bax in non-apoptotic cells is necessary for mitochondrial bioenergetics, and have identified the 
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CHAPTER 1: GENERAL INTRODUCTION 
“Life is pleasant, death is peaceful. It‟s the transition that„s troublesome.” Isaac Asimov 
Apoptosis is a cell death program that is critical for cellular and tissue homeostasis and is 
also a key pathologic feature of various diseases.  Over the past decade, the role of mitochondria 
has been increasingly recognized as an important mediator for the apoptotic process, and release 
of mitochondria apoptotic factors is considered as the “point of no return” in apoptotic signaling 
[1-3].  Upon an apoptotic stress signal, the permeabilization of the outer mitochondrial 
membrane (OMM) allows the release of cytochrome c and other apoptotic proteins from the 
intermembrane space of mitochondria, leading to the activation of the caspase cascade and 
apoptotic cell death [2,3].  This process is in part regulated by the Bcl-2 family of proteins, 
which can be classified into three groups based on their structure and their role in apoptosis: (1) 
the pro-apoptotic proteins, such as Bax and Bak, which contain three Bcl-2 homology (BH) 
domains BH1, BH2, and BH3; (2) the anti-apoptotic proteins like Bcl-2, Bcl-XL, Bcl-w and Mcl-
1, which contain four homology domains BH1, BH2, BH3 and BH4; and (3) the BH3-only 
proteins such as Bid, Bim and Bad, which induce apoptosis by either activating pro-apoptotic 
proteins like Bax or by suppressing anti-apoptotic proteins like Bcl-2.  Most of these proteins 
share one to four BH-domains and contain a C-terminal hydrophobic α-helix that is involved in 
their localization to either the OMM or endoplasmic reticulum (ER) membranes [4-7].  Bax 
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participates in the induction of apoptosis in response to a variety of stimuli, and Bax 
conformational changes and translocation into the OMM is recognized as a key event triggering 
mitochondria-dependent apoptosis [1, 3, 7].  
Bax is a 21 KD pro-apoptotic protein of 192 amino acids comprising 9 alpha helices [8].  
The hydrophobic α5-α6 hairpin helix is located in the central core surrounded by 7 amphipathic 
α-helices.  NMR data on the 3-D structure of Bax shows that alpha helix 9 is situated within a 
hydrophobic groove.  Generally, the localization of Bax is cytosolic in most healthy cells, 
although some mitochondria localization has been described [Putcha et al., 1999, 2002; 
Kaufmann et al., 2004].  Many functions of Bax can be attributed to specific domains.  The BH3 
domain is mostly found in the alpha 2 helix and  has been shown to be involved in the hetero-
dimerization with other Bcl-2 family proteins [9-11].  The hydrophobic helix 9 and helices 5/6 
has been implicated in the activation, self-association and mitochondria membrane binding of 
Bax [11-14].  
The translocation of Bax from the cytosol to the OMM is a critical event in apoptosis.  
Although the precise mechanism remains to be elucidated, two models of Bax activation have 
been proposed to explain the activation of Bax during apoptosis [7, 15].  Briefly, in the first 
model, upon apoptotic stimuli the BH3-only Bcl-2 family proteins interact with Bax, leading to 
conformational changes that result in the formation of oligomers and insertion into the OMM.  In 
the second model, the conformational changes of Bax occurs in the cytosol leading to release of 
the C-terminal α9 helix from the hydrophobic grove, thereby exposing the previously hidden 
BH3 domain.  Bax then inserts into the OMM either through its N-terminus [14,16,17] or its C-
terminus [18-20].  Studies from our group and others showed that pH could induce a 
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conformational change in Bax, resulting in the C-terminal and BH3 domain being exposed, 
leading to mitochondria translocation [21, 22].  Others have shown that Bax can insert into 
membranes as a monomer, suggesting that the insertion step occurs prior to oligomerization [23].  
How Bax translocates to the OMM is still a matter of debate. 
Recently, it was suggested that Bax C-terminus is required for Bax translocation to 
mitochondrial during apoptosis [18-20].  Some reports suggest that the C-terminal anchor is not 
required for Bax translocation during apoptosis [14, 25].  Deletion of the C-terminal 22 amino 
acids failed to block recruitment of Bax to mitochondria during apoptosis [22].  While others 
studies showed that the C-terminus is needed to translocate Bax to mitochondria.  As example, 
mutating proline 168, upstream of the C-terminus prevented Bax translocation during apoptosis 
and abolished its apoptotic activity (16, 19, 20).  Despite
 
these findings, whether the C-terminus 
of Bax is a membrane binding domain or a regulatory domain remains to be analyzed.  We 
performed computational-mutagenesis studies to determine the potential amino acids of the C-
terminus necessary for Bax membrane binding activity. Based on the differences in helical 
packing energy, we predicted that lysine 189 and lysine 190 at the C-terminus may be crucial for 
Bax membrane binding (Khaled A, unpublished data).  However, this hypothesis has not been 
validated in a cell model system.  
Under physiological conditions, Bax usually resides in the cytoplasm and translocates to 
mitochondria upon apoptotic stimuli.  In its inactive form, Bax is also found in very low numbers 
in mitochondrial membranes [7, 8].  Thus, Bax localizes to mitochondria as its major site of 
action.  Some studies have shown that Bax is involved in the formation of ion-conducting pores 
in the mitochondria membrane [26-28].  Bax may functionally interact with components of the 
4 
 
mitochondrial inner membrane, like the adenine nucleotide transporter (ANT), the mitochondrial 
F0F1 ATPase H
+
 pump, and the outer membrane voltage-dependent anion channel [29-31].  Bax 
could also directly interact with the mitochondria channel Kv1.3 in lymphocytes [28].  Recently, 
Bax was shown to participate in mitochondrial reactive oxygen formation in non-apoptotic 
neuron cells [32, 33].  These findings imply that Bax’s interaction with mitochondria may play 
an important role in regulation of mitochondrial function.  However, the functional significance 
of the interaction of Bax with mitochondria under non-apoptotic conditions has not been 
determined.  It is unknown whether the C-terminus of Bax is the critical region responsible for 
the function of non-apoptotic form of Bax.  
Here we investigate the role of Bax in the regulation of mitochondrial function under 
non-apoptotic conditions and explore the molecular mechanisms for Bax translocation to 




 HCT-116 cells, we examined Bax 
cellular localization and its effects on mitochondrial bioenergetics in non-apoptotic cells.  We 
further tested whether over-expression of full-length Bax in Bax
-/-
 cells would restore 
mitochondrial metabolic activity.  We also over-expressed a C-terminal truncated Bax (Bax-
ΔCT) in Bax
-/-
 cells to determine whether the C-terminal helix of Bax is crucial for 
mitochondrial bioenergetics.  We showed that Bax localized to outer and inner mitochondrial 
membranes in non-apoptotic cells, affecting citrate synthase activity, intracellular ATP 
production and oxygen consumption.  Loss of Bax led to impairment of mitochondria respiring 
morphology and oxidative capacity, all of which can be restored by expression of full-length 
Bax.  We also found that expression of the C-terminal truncated Bax can also restore 
mitochondrial bioenergetics.  These findings indicate that the constitutive expression of Bax in 
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non-apoptotic cells is associated with mitochondria and is necessary for mitochondrial 
bioenergetics.  
To determine the molecular mechanisms for Bax targeting to mitochondria under 
apoptotic stimuli, we previously performed in silico mutagenesis and predicted that lysines 
189/190, in the C-terminal α9 helix, could regulate the membrane binding activity of Bax.  A 
series of in vitro mutagenesis were performed.  Data presented here demonstrate that these 
lysines are the functional domain contribute to the mitochondrial translocation of Bax under 
apoptotic stimuli.  Expression of full-length Bax led to mitochondrial translocation and 
apoptosis, whereas deletion of the α9 helix resulted in cytosolic retention, and no apoptosis.  
Mutation of the two lysine residues changed the localization of Bax from either the cytosol or 
mitochondria.  We replicated the results achieved with full-length Bax by attaching just the last 
20 residues of the α9 helix of Bax either to GFP or to a regulatory element: a degradation domain 
(DD), and induced apoptosis upon expression in cells.  We demonstrated that the α9 helix alone 
promoted the mitochondrial translocation of either GFP or the DD and induced apoptosis.  These 
results indicate that the C-terminal α9 helix alone is sufficient to induce cell death and therefore 




CHAPTER 2:  BAX SUPPORTS THE MITOCHONDRIAL NETWORK, 
PROMOTING BIOENERGETICS IN NON-APOPTOTIC CELLS 
Data presented here in part has been published at Am J Physiol Cell Physiol (February 2, 2011). 
Introduction 
As a pro-apoptotic protein, Bax has been established in participating in the induction of 
apoptosis in response to a variety of apoptotic stimuli [1-3, 9].  Under physiological conditions, 
Bax usually resides in the cytoplasm in most healthy cells, although a fraction of the cellular Bax 
pool is found to be associated with the outer mitochondria membrane [7, 8].  Over the past 
decades, most studies focused on how Bax translocates to mitochondria and triggers apoptosis, 
little is known about the functional significance of Bax in non-apoptotic cells.  Recently, the 
essential role of Bax in non-apoptotic cells has emerged.  It has been reported that Bax 
participates in mitochondrial production of reactive oxygen species in non-apoptotic sympathetic 
neuron cells [32, 33].  However, how Bax does this is unknown.  Since Bax uses mitochondria as 
its major site of action, we postulated that Bax may interact with mitochondria and be involved 
in the regulation of mitochondria function.  To test this possibility, mitochondrial bioenergetics 
were examined in Bax-containing (Bax
+/+
) and Bax-deficient (Bax
-/-
) HCT-116 cells.  Our results 
showed that some of the cellular Bax localized to the outer and inner mitochondrial membranes 
in non-apoptotic cells and participated in citrate synthase activity, intracellular ATP production 
and oxygen consumption.  Loss of Bax led to impairment of mitochondria respiration, 
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morphology and oxidative capacity, all of which could be restored by expression of full length 
Bax.  These findings indicated that in non-apoptotic cells, the constitutive expression of Bax is 
associated with mitochondria and is necessary for mitochondrial bioenergetics. 
Materials and Methods 





 HCT-116 colorectal cancer cell lines (a kind gift from Dr. Bert 
Vogelstein, John Hopkins University) were grown and maintained in McCoy’s 5A Medium 
(Gibco), 10% Fetal Bovine Serum (FBS) and 1% Penicillin-Streptomycin.  FCCP 
(carbonylcyanide-p-trifluoro-methoxyphenylhydrazone) (Sigma) was used at a concentration of 
5 µM as described below.  This was determined to be the optimal concentration after performing 
a titration experiment (FCCP 0-25 μM) and measuring effects on 100 cell viability and ATP 
production as described below. 
Plasmids, Mutagenesis, and Transfection 
  PCR-directed deletion of the C-terminus of Bax to generate the C-terminal truncated 
form of Bax (Bax- CT) was performed using untagged primer sets and was confirmed by 
sequencing.  BAX was PCR amplified from the template, pEGFP-Bax (a gift from Dr. Richard 
Youle, NINDS, NIH).  To examine the transient expression of the DD-tagged full length (Bax-
FL), DD-tagged Bax- CT, DD-tagged C-terminal Bax peptides (DD-CT-Bax) constructs, 
bicistronic ProteoTuner vectors (CloneTech) containing these Bax inserts and green fluorescent 







 HCT-116 cells.  Expression of the Bax constructs was induced upon the addition of 
Shield 1 (CloneTech) at a concentration of 1uM.  The plasmid DNA was delivered at a 
concentration of 1µg/mL using the TransIT-LT1 transfection reagent (Mirus) following 
manufacturer’s protocol.  Transfection efficiency was determined microscopically by visualizing 
GFP expression after 18 hours, and ranged from 50-70%.  Experiments were performed within 
defined timeframes to ensure optimal cell viability, prior to any induction of apoptosis. 





 HCT-116 cells were cultured in a BD Oxygen Biosensor plate at a 
concentration of 50,000 cells per well.  The biosensor plate contained an oxygen-sensitive dye 
embedded in a gas-permeable matrix.  Based on the properties of this dye, oxygen quenches the 
ability of the dye to fluoresce.  The dissolved oxygen in the medium is depleted by the cells 
metabolizing in the well, resulting in an increase in fluorescence.  This allows a correlation of the 
rate of oxygen consumption to be made.  The plate was read at 37ºC on an EnVision plate reader 
(PerkinElmer) using ex/em wavelengths of 485/630nm.  Fluorescence intensity was measured 
every hour for 24 hours.  For comparisons of oxygen consumption rate (OCR) and extracellular 




 HCT-116 cells were seeded at 40,000 cells/well in a 
24 well Seahorse cell culture plate.  Full-length and CT Bax constructs were transfected into 
Bax
-/- 
cells for measurement as well.  The transfected cells were treated with shield 1 three hours 
prior to reading to induce expression of the protein.  Measurements were taken on the Seahorse 




Mitochondrial Staining, Fixed- and Live-Cell Imaging 
  For fixed cells, Bax
+/+
 HCT-116 cells were plated onto coverslips coated with 10µg/mL 
laminin (Invitrogen).  Cells were plated at a density of 50,000 cells/well and were fixed by 
methanol.  The cells were then probed with anti-BAX (N-20; Santa Cruz) and anti-HSP60 (H-
300; Santa Cruz) antibodies, followed by FITC and CY3 secondary antibodies. Images were 
scanned using the LSM 510 (Zeiss) with a 100x/1.4 plan-apochromat objective.  The scanned 





 HCT-116 cells were grown and plated in 24-well glass bottom dishes (MatTek) that had 
been pretreated with 1N HCl and coated with10ug/mL laminin.  The cells were plated at 10,000 
cells per well and allowed to grow over night.  Bax-FL or Bax- CT constructs were transfected 
using the TransIT-LT1 transfection reagent (Mirus) and expressed as previously described At 18 
hours post-transfection, cells were incubated with 1uM MitoTracker Red 580 or 5µM 10-Nonyl 
Acridine Orange (NAO) (Molecular Probes) in McCoy’s complete media for 30 minutes prior to 
imaging.  Treatments with 5µM FCCP were done 15 minutes prior to imaging.  Fluorescent 
images were acquired with the UltraView spinning disc confocal system (PerkinElmer) with 
AxioObserver.Z1 (Carl Zeiss) stand, and a Plan-Apochromat 63x/1.4 Oil DIC objective. Z-stack 
projections of the scanned images were generated and modified within the Volocity image 
processing program (PerkinElmer). 





 HCT-116 cells were plated in 75cm flasks and grown to 70-80% 
confluence.  Cells were transiently transfected with the Bax-FL or Bax- CT constructs and 
protein expressed as previously described. At 18 hours post transfection, the cells were lifted and 
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pelleted.  The pellets were resuspended and lysed according to the protocol from the 
Mitochondrial Enrichment Kit (Pierce).  Note that a low speed centrifugation step in the 
mitochondrial enrichment process ensures that only intact and unfragmented mitochondria are 
isolated.  The enriched mitochondria were layered on an iodixanol gradient (6%, 10%, 15%, 
20%, 23%, and 27%) and subjected to ultracentrifugation using an Optima L-100XP 
Ultracentrifuge for 2 hours at 145,000 rcf in a SW55.1 swing bucket rotor (Beckman Coulter).  
After centrifugation, each sample was unloaded in 500uL fractions using a fraction recovery 
system (Beckman Coulter), and washed in ice cold PBS twice (18,000 rcf, 30 minutes) to remove 
residual iodixanol.  The pellets from each of these fractions were resuspended in 1x loading 
buffer and run on 8-16% Tris-glycine gradient gels (Invitrogen).  The gels were transferred to 
PVDF membranes and probed with primary antibodies to Bax (N-20; Santa Cruz), Prohibitin 
(ABCAM), and GRP78 (Santa Cruz), followed by incubation with the appropriate HRP 
conjugated secondary antibodies (Santa Cruz, Cell Signaling) and developed by 
chemiluminescence (Pierce). 





 HCT-116 mitochondria were isolated as above.  The mitochondria 
were then treated with Proteinase K (Sigma) (10 µg/ml) for 5, 10, 15 or 20 minutes in order for 
the outer mitochondrial membrane associated proteins to be digested.  The reaction was 
terminated with PMSF [35].  The mitochondria were then washed with isotonic buffer, pelleted, 
resuspended in 1X sample buffer and run on 12% acrylamide gels in parallel with untreated 
mitochondria.  The gels were transferred to PVDF membranes which were then probed with Bax 
(N-20; Santa Cruz), as well as Bcl-XL (2762, Cell Signaling) primary antibodies, followed by 
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incubation with anti-mouse or anti-rabbit IRDye 800CW secondary antibodies (Licor).  The 
membranes were imaged using the Licor Odyssey Infrared Imaging system. Densitometry 
measurements were made using Image J. 
Measurement of ATP production and Mitochondrial Membrane Potential 
  Cells were seeded and treated in 24 well plates overnight.  The cells were then lifted, 
counted and seeded in 96-black well flat-bottom plates at a density of 4,000-5,000 cells/well.  To 
uncouple oxidative phosphorylation, 5µM FCCP was added to the cells two hours prior to 
analysis of ATP concentration.  ATP levels were quantified using the ATPLite 1-Step assay kit 
(PerkinElmer).  Luciferase activity, reported as Relative Luminescence Units (RLU), was 
measured on an EnVision (PerkinElmer) plate reader.  The luminescence was normalized to the 
number of cells/well.  Additionally a standard curve of known ATP concentrations was 
established to ensure that the experimental values were within an accurate range.  Background 
signal was corrected for by subtracting the values of an empty plate. In addition, as the 
fluorescence of MitoTracker Red 580 (Invitrogen) is a result of oxidation of the compound 
within the mitochondrial matrix, changes in MitoTracker fluorescence intensity was used to 
assess the qualitative and quantitative efficiency of the electrochemical potential (the relative 
oxidative capability of actively respiring mitochondria [36].  Measurements of mitochondrial 
content, membrane potential, and viability were done by staining the cells with both ethidium 
bromide (Fisher Scientific) and NAO (6).  Briefly, 500,000cells/sample was stained with 
25ng/mL NAO and 40ng/mL ethidium bromide for 10 minutes.  The cells were then washed 3 
times with 0.1% BSA in PBS at 4ºC for 10 minutes at 1000g.  The cells were read using the C6 
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flow cytometer (Accuri) using the FL1 and FL3 channels. Data was analyzed using FCSExpress 
(DeNovo). 
Measurement of Citrate Synthase Activity 




 HCT-116 cells were assayed for citrate 
synthase activity.  The citrate synthase enzyme catalyzes the reaction: CoA-SH + DTNB  TNB 
+ CoA-S-S-TNB.  The rate of TNB formation is linear and has a measurable absorbance at 
412nm.  The rate of TNB generation (μMol/ml/min) was measured by spectrophotometry 
(Beckman Coulter SD8000) for 200 seconds.  Mitochondrial samples were run in Tris buffer to 
determine inner mitochondrial membrane integrity (reported as % ruptured mitochondria), or 
Tris buffer with Triton X-100 to determine citrate synthase activity. 
Measurement of Mitochondrial DNA 




 HCT116 cells using TRIZOL Reagent 
(Invitrogen) followed by ethanol precipitation.  Resuspended DNA pellets were analyzed for 
nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) content.  Primers for the detection of 
the nuclear housekeeping gene β-actin and for the mitochondrial DNA encoded ATPase 
(MTATP) genes were as follows: β-actin (forward): 5’-GAA ATC GTG CGT GAC ATC 
AAAG; (reverse): 5’-TGT AGT TTC ATG GAT GCC ACAG. MTATP (forward): 5’-AAT ATT 
AAA CAC AAA CTA CCA CCT ACC; (reverse): 5’- TGG TTC TCA GGG TTT GTT ATA 
[37].  The PCR was carried out in a 7500 Fast real-time PCR system (Applied Biosystems).  All 
reactions were carried out in 20μl of total reaction volume containing 1μg/μl total DNA, 
appropriate primers and Fast SYBR Green Master Mix (Applied Biosystems).  Each reaction 
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underwent a 30 s 90 ºC denaturation followed by 40 cycles of 30 s at 60 ºC then 3 s at 95 ºC.  All 
samples were analyzed in triplicate.  The relative amount of mtDNA (normalized to nuclear 
content) is represented as 2ΔCt, calculated using the following equation: ΔCt = (CtmtDNA 
/CtnDNA) - (CtnDNA/CtnDNA), where Ct is the cycle threshold for each condition. 
Statistics 
All data in this study are expressed as means ± SEM. Statistical analysis of differences in 
data between the groups was determined using Prism for Windows, Version 5.02 (GraphPad 
Software Inc). 
Results 
Bax is essential in mitochondrial bioenergetics  
To determine whether Bax has a previously unrecognized non-apoptotic activity, we 





colon cancer cells.  Mitotracker Red 580 fluorescence intensity was used as an indicator of 
oxidative capacity and to visualize actively respiring mitochondria [38].  Live-cell imaging was 
performed to ensure that fixatives would not disrupt MitoTracker uptake.  As shown in Figure 
1A, when Bax is present, we observed respiring mitochondria that displayed elongated and 
tubular shape with a loosely dispersed branching network.  In contrast, when imaging of the Bax
-
/-
 cells, we observed that the respiring mitochondria were numerous but appeared less elongated 
due to the deficiency of Bax (Fig. 1B).  To verify that the observed differences in functional 
morphology upon Mitotracker staining were not due to alterations in the fission/fusion process, 
14 
 
treatment with Mdivi 1, a chemical inhibitor of DRP1that prevents fission by blocking the early 
stages of DRP1 assembly, resulted in uniform changes in MitoTracker fluorescence that were 
independent of Bax (data not shown). 
To determine whether the differences observed in Mitotracker staining (Figs. 1A, 1B) 





 HCT-116 cells with N-nonyl acridine orange (NAO).  NAO accumulates in mitochondria 
by binding to phospholipids, specifically cardiolipin [39, 40].  Hence NAO accumulation is 
independent on mitochondrial respiration and would directly show mitochondrial content.  As 





HCT-116 cells.  This was confirmed by the measurement of total NAO fluorescence in 
each cell population (Fig. 1C).  Hence, total mitochondrial density or content was independent of 
Bax expression.  To confirm results from NAO staining, we perform a quantitative experiment 
by measuring total mitochondrial DNA (mtDNA) relative to nuclear DNA (nDNA).  We found 




 HCT-116 cells (data not 




 HCT-116 cells were equally viable, we stained 
cells with NAO and ethidium bromide (EB).  EB stains DNA only when the cell membrane is 
ruptured, as it is in cultured apoptotic cells.  Representative data displayed in Fig. 1D revealed 
that there were no significant Bax-dependent differences in overall viability.  The viability of cell 
lines used in all experiments reported herein was consistent with the data shown in Figure 1D.  
Together, these results suggest that the observed morphological differences detected by 
mitochondrial tracker staining were due more to a functional defect rather than decreased 
mitochondrial content.  
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To explore a possible functional defect upon BAX loss that was revealed by Mitotracker 
staining, we examined the electrochemical properties of the mitochondria in the two HCT-116 
Bax variants using the uncoupling agent, FCCP. FCCP is a hydrophobic compound that carries 
protons across the IMM, releasing these protons into the matrix allowing for the dissipation of 
the chemiosmotic gradient.  A titration of FCCP was previously performed to determine the 
optimal concentration of FCCP for use, that is, caused the least effect on cell viability and the 
most effect on ATP production (data not shown).  When treated with FCCP, Bax
+/+ 
mitochondria 
displayed a stronger intensity of Mitotracker fluorescence compared to untreated cells (Fig. 2A, 
2C).  This was not observed in Bax
-/-
 cells (Fig. 2B, 2C).  Although relaxation of Mitotracker 
fluorescence quenching has been reported with FCCP, we do not think this artifact is the reason 
for the observation made with Bax
+/+
 cells, since the increase in Mitotracker fluorescence was 
not repeated in Bax
-/-
 cells.  Quantification of the effect of FCCP treatment revealed a two fold 
increase in MitoTracker fluorescence in Bax
+/+
 cells compared to untreated cells that was not 
observed with Bax
-/-
 cells (Fig 2C).  We propose that, in Bax
+/+
 cells, the FCCP-mediated 
uncoupling of the electron transport system results in the rapid oxidation of matrix substrates, 
such as MitoTracker Red 580, which can be detected as an increase in MitoTracker fluorescence 
[39].  This does not occur in Bax
-/-
 cells, suggesting that loss of Bax may cause a defect in 
mitochondrial oxidative capacity.  Bax
-/-
 cells also had significantly decreased levels of 
intracellular ATP as compared to Bax
+/+
 cells (Fig. 2D).  Furthermore, FCCP treatment resulted 
in a marked drop in ATP levels in Bax
+/+
 cells, but not in Bax
-/-
 cells (Fig. 2D).  Note that a 
previous titration of FCCP concentrations correlated with ATP amounts detected, indicating that 
we were primarily assessing changes in ATP production (data not shown).  
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To determine whether the loss of ATP in Bax
-/-
 cells was due to abnormal bioenergetics, 





HCT-116 cells was assessed by plotting the oxygen consumption rate 
[OCR], a measure of mitochondrial respiration, against the extracellular acidification rate 
[ECAR], an indicator of glycolysis.  Comparing changes that occur in aerobic and glycolytic 
metabolism, shown in Figure 2E, revealed that Bax
+/+ 
cells had increased oxygen consumption 
(OCR) and decreased glycolytic activity (ECAR) relative to Bax
-/-
 cells; hence cells deficient in 
Bax were more dependent on glycolysis for their energy needs.  A separate measure of oxygen 
consumption, using an alternative method, further confirmed these findings (Fig. 2F).  Taken 
together, these results indicated that the decreased levels of ATP observed in Bax
-/-
 cells were 
likely due to depressed respiration, suggesting that cells lacking Bax had a significant defect in 
oxidative capacity. 
Bax associates with mitochondria and contributes to ATP production 
 Since we showed a non-apoptotic function for Bax in the regulation of mitochondrial 
metabolism, immunofluorescence was performed to determine whether Bax localizes to 
mitochondria in the absence of apoptosis.  As shown in Figure 3A, a partial overlay of Bax with 
mitochondria (HSP-60 staining for mitochondrial marker) was observed in Bax
+/+
 HCT-116 
cells.  To determine the interaction of Bax with mitochondria under standard growth conditions, 
ultra centrifugation of enriched mitochondria was performed to examine the localization of Bax.  
Cell lysates were prepared from cells that had the same viability.  The enriched mitochondrial 
lysate was layered on an iodixanol gradient and subjected to ultracentrifugation as described in 
methods.  Separation of organelles was based on density, which is a function of the protein-lipid 
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ratio of the organelles.  Western blot analysis of the gradient fractions for Prohibitin 





 HCT-116 cells was similar (across the 20-23% fractions).  Approximately 7% 
of the total endogenous Bax was detected in the non-apoptotic Bax
+/+
 cells associated with the 
mitochondrial fractions, while no Bax was detected in Bax
-/-
 cells (Fig. 3B).   
To determine whether Bax was loosely associated with mitochondria (i.e. bound to the 
outer mitochondrial membrane (OMM)) or whether it was sequestered within an inner membrane 
compartment (IMM). Enriched mitochondrial lysates were treated with Proteinase K for 5 to 20 
minutes.  Digested lysates were analyzed by SDS-PAGE and immunoblotted with antibodies to 
detect Bax and, as a control, BCL-XL. BCL-XL is mainly an OMM localized protein and 
sensitive to protease digestion.  We found that treatment with Proteinase K resulted in 50-60% 
lysis of Bax, compared to BCL-XL, in which 77-100% of the protein was lysed (Fig. 3C).  
Although in the same sample there was less BCL-XL protein detected compared to Bax, an 
increase in the amount of BCL-XL digested occurred over time, while Bax was mostly digested 
within 5 minutes.  These results suggest that a significant amount of Bax was sequestered within 
the mitochondria and not accessible to be digested by the protease.  Hence Bax has both outer 
and inner mitochondrial localization, supporting its proposed role in mediating mitochondrial 
respiration.  The ability of Bax to regulate mitochondrial metabolism was further demonstrated 
by measurements of citrate synthase activity, which localized to the mitochondrial matrix and is 
one of the first enzymes of the tricarboxylic cycle.  As shown in Figure 3D, Bax
-/-
 cells had 
reduced levels of citrate synthase activity in comparison to Bax
+/+
 cells.  
18 
 
Expression of full-length Bax restores mitochondrial metabolic activity in Bax
-/-
 cells 
Since cells lacking of Bax displayed impaired mitochondrial metabolic activity, we 
determined whether restoring Bax to deficient cells would rescue mitochondrial metabolic 
activity.  Over-expression of full-length Bax (Bax-FL) in Bax
-/-
 cells resulted in recovery of 
respiring mitochondria morphology as observed in Bax
+/+
 cells (Fig. 4A).  Western blot analysis 
of density gradients showed that ~2.5% of the total expressed protein associated with 
mitochondrial fractions (Fig. 4B).  We also observed a three-fold increase in ATP production 
upon the expression of Bax-FL, whereas this increase in ATP production was inhibited by 
treatment with FCCP (Fig. 4C), suggesting that that Bax-FL could rescue ATP production 
through oxidative phosphorylation. ECAR/OCR measurements further confirmed that expression 
of Bax-FL could increase oxygen consumption and reduce glycolytic activity, indicating that 
Bax was a critical regulator of these activities (Fig. 4F).  To determine the contribution of the C-
terminal helix of Bax to mitochondrial bioenergetics, over-expression of C-terminal truncated 
Bax (Bax-ΔCT) in Bax
-/-
 cells was performed.  As shown in Figure 4D, expression of Bax-ΔCT 
did not restore the respiring mitochondrial morphology seen in the presence of Bax, suggesting 
that the C-terminal domain of Bax is essential to regulate mitochondrial metabolic activity by 
Bax.  The removal of this C-terminal helix also resulted in a scattered localization of Bax-ΔCT, 
which was supported by the altered banding pattern in the gradient fractions (Fig. 4E).  Even 
though mitochondrial targeting was deregulated in this mutant, Bax-ΔCT was found in the 
mitochondrial fractions (~9%, Fig. 4E), and was able to restore ATP production as effectively as 
Bax-FL (Fig. 4E).  This was further demonstrated by measurements ECAR/OCR, which showed 
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that expression of Bax-ΔCT was able to restore metabolic balance in Bax
-/-
 cells, almost the same 





Figure 1. Loss of Bax leads to altered respiring mitochondria morphology. 
 Bax+/+ HCT-116 cells (A) and Bax-/- HCT-116 cells (B) were treated with MitoTracker Red 
580 or NAO prior to imaging as described in Methods.  Live cell images were obtained using the 
UltraView (PerkinElmer) spinning disc confocal system.  Images are representative of three 
replicates per condition.  Insets are 10X magnification of the two highlighted areas in each field. 
(C) and (D)  To assess mitochondrial density (C) and viability (D), 500,000 cells/sample were 
stained with NAO (C) or NAO and ethidium bromide (EtBr) (D) for 10 minutes.  Fluorescence 
output was read using the FL1 and FL3 channels on a C6 flow cytometer (Accuri).  Each 






Figure 2. Loss of Bax leads to reduced mitochondrial oxidative capacity. 
Bax+/+ HCT-116 cells (A) and Bax-/- HCT-116 cells (B) were treated with FCCP in McCoy’s 
complete media for two hours prior to imaging.  Live cell images were obtained using the 
UltraView spinning disc confocal system.  The stand was a Zeiss AxioObserver Z.1 with a Plan-
Apochromat 63x/1.4 Oil DIC objective.  Insets are 10X magnification of the two highlighted 
areas in each field.  Images are representative of three separate experiments with two replicates 
per condition. (C)  Calculation of Mitotracker fluorescence intensity was done with Velocity 
software by averaging the mean intensity of the pixels in each fluorescent cell.  (D) ATP 
concentration was assessed by measuring the activity of Luciferase as relative luminescence 
units (RLU).  (E) OCR and ECAR data obtained from the Seahorse XF24 Analyzer was 
calculated based on the oxygen consumption and acidification rates of 40,000 cells per well.  The 
values were pooled from three separate experiments and normalized to changes from the initial 
rate, n=9. (F) Oxygen consumption in both Bax+/+ and Bax-/- cells was measured over time as a 
function of increased fluorescence.  Fluorescence, oxygen biosensor, and ATP data are 
representative of n=6.  The values for the ATP, OCR and ECAR assays were normalized to cell 
number per well, and statistics were done using One-way ANOVA with Dunnett’s post-test 























Figure 3. Bax associates with mitochondria in non-apoptotic cells resulting in reduced citrate 
synthesis activity.  
(A) Bax+/+ HCT-116 cells were fixed and stained with the indicated fluorochrome-conjugated 
antibody as described in Methods.  Confocal microscopy of cells shows endogenous Bax (green), 
the mitochondrial protein, HSP60 (red), and the merged field (yellow) indicating co-localization 
of Bax with HSP60.  Images were acquired with LSM 510 using 100 x/1.4 Oil DIC objectives 
and are representative of ten different images scanned from three separate experiments.  (B) 




and Bax-/- HCT-116 cells and subjected to differential ultracentrifugation as described in 
methods.  Gradient fractions collected were analyzed by SDS-PAGE and membranes probed for 
the presence of Bax, prohibitin (mitochondria), and GRP78 (ER).  Each blot shown is 
representative of three independent experiments.  (C) Western blot analysis of mitochondria 
isolated from BAX+/+ cells shows the effects of Proteinase K digestion on mitochondrial 
membrane proteins over time.  The extent of the digestion was calculated based on the percent 
change in densitometry between the treated and untreated samples.  (D) The assessment of citrate 
synthase activity was determined by the rate of formation of thionitrobenzoic acid as described in 
methods.  The rate of activity is shown as μMol/ml/min.  Background levels of citrate synthase 
activity in spontaneously ruptured mitochondria are included as controls.  The data encompasses 
two separate experiments for a total of n=4 per sample.  Statistics were calculated using unpaired 
Students t-test. *P < 0.05. BCL-XL is mainly an OMM localized protein and sensitive to 
























Figure 4. Expression of full-Length Bax restores mitochondrial association and ATP production 
in Bax
-/-
 cells.  
Bax
-/-
 716 HCT-116 cells were transfected with a ProteoTuner bi-cistronic vector expressing 
either full-length (FL) Bax (A, B) or Bax- CT(C, D) and GFP(A, C) Cells were grown on 




1 was added to induce expression.  Transfected cells were imaged based on GFP expression, and 
MitoTracker Red was used for mitochondria visualization.  Live cell images were obtained using 
the UltraView spinning disc confocal system.  The stand was a Zeiss AxioObserver Z.1 with a 
Plan-Apochromat 63x/1.4 Oil DIC objective with a resolution of 0.124 m. Insets were acquired 
at 10 X magnifications.  Post-acquisition processing was done using Velocity software. (B, D)  
Bax-/-HCT-116 cells were transfected with either Bax-FL or Bax- CT as described above.  
Mitochondrial enriched lysates were subjected to differential ultracentrifugation and SDS-PAGE 
as described in methods.  Membranes were probed with antibodies for Bax, prohibitin 
(mitochondria) and GRP78 (ER).  Images are representative of three independent experiments.  
(E) Bax+/+ and Bax-/- HCT-116 cells transiently transfected with Bax-FL or Bax- CT ( C) 
were treated with and without FCCP and analyzed for changes in ATP levels as described in 
Methods.  (F) Bax+/+ HCT-116 cells, Bax-/-HCT-116 cells, and Bax-/- HCT-116 cells, 
transiently transfected with Bax-FL (FL) or Bax- CT ( CT or DCT,) were analyzed for changes 
in OCR and ECAR as in methods.  One-way ANOVA was used for statistical analysis.  
Microscopy and ATP data is representative of two experiments each with three replicates. OCR 
and ECAR data are representative of two experiments with a total of six replicates.  Statistical 
results for OCR and ECAR assays are *p <0.05for Bax-/- vs. Bax-FL and Bax-/- vs. Bax- CT. 





The Bcl-2 family proteins that tightly control the mitochondrial pathway of apoptosis 
have been classified into pro- and anti-apoptotic members [7,9].  Among which Bax is a pro-
apoptotic protein, and its activation is a highly regulated, multi-step process that involves Bax 
conformational changes, mitochondrial translocation and oligomerization, and ultimately leading 
to mitochondrial dysfunction and apoptotic cell death [1-3,7].  Although the precise mechanisms 
remain unclear, it is generally accepted that Bax conformational changes and translocation to the 
mitochondria are critical events for Bax to exert it apoptotic activity upon apoptosis stimuli [7,9].  
In dying cells the accumulations of activated Bax at the mitochondrial outer membrane trigger 
the release of apoptotic mediators, such as cytochrome c, from the intermitochondrial membrane 
space.  Thus, Bax localizes to and uses mitochondria as its major site of action. In addition to its 
apoptotic form, Bax is also constitutively expressed in non-apoptotic cells and resides in a 
soluble, cytosolic form or associated with mitochondria [7, 8].  Several studies have 
demonstrated that this non-apoptotic form of Bax may be involved in mitochondrial function 
such as reactive oxygen formation and ion channel conduction [32, 33].  However, relatively 
little is known about the direct role that the inactive form of Bax plays in regulation of 
mitochondrial function. 
In the present study, we assessed the direct role of non-apoptotic Bax in mitochondrial 




 HCT-116 cell model system.  The 
results showed that Bax localized to outer and inner mitochondrial membranes in non-apoptotic 
cells and participated in citrate synthase activity, intracellular ATP and oxygen consumption.  
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Loss of Bax led to impairment of mitochondria respiring morphology and oxidative capacity, all 
of which could be restored by expression of full-length Bax.  These findings indicated that under 
normal conditions, the constitutive expression of non-apoptotic Bax is associated with 
mitochondria and is necessary for mitochondrial bioenergetics. 
Under non-apoptotic conditions, Bax is present in a soluble, cytosolic form or associated 
with mitochondria as a monomer.  A small amount of “active” (non-apoptotic) BAX associated 
with healthy mitochondria may contribute to the regulation of functional architecture and 
bioenergetics of mitochondria.  This leads to the hypothesis that BAX associated with 
mitochondria under non-lethal conditions could be restricted by the lipid and protein composition 
of the organelle membrane [41, 42].  Apoptosis induces changes in mitochondria that could help 
recruit Bax, while, in the absence of apoptosis the outer mitochondrial membrane environment is 
less likely to support the translocation of Bax.  In mitochondria from healthy cells, a few BAX 
monomers or dimers may insert into the mitochondrial membranes to form small pores, but this 
process needs to be tightly regulated.  Bax may also functionally associate with components of 
the mitochondrial inner membrane, like the adenine nucleotide transporter (ANT), the 
mitochondrial F0F1 ATPase H
+
 pump, and the outer membrane voltage-dependent anion channel 
(VDAC) [29-31]. Thus, it is more feasible for Bax to be interacting with existing mitochondrial 
proteins.  This possibility is supported by our findings that a portion of Bax was sequestered 
within the mitochondria, perhaps interacting with an IMM protein.  Hence, the amount of Bax 
associated with mitochondria in non-apoptotic cells would be constrained by the availability of 
the binding partner(s), although most were discovered in the context of an apoptotic scenario 
[29-31].  In addition to ANT and VDAC, many other proteins are known to interact with Bax, 
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including factors that mediate changes in the mitochondrial network such as fission or fusion 
proteins like Drp1[43], Mfn-2 [44] or endophilin B1 (Bif-1) [45] as well as other regulatory 
proteins such as cyclophilin D or Ku70[46].  Although this may seem speculative, the excess of 
circumstantial evidence for the interaction of Bax with healthy mitochondria highlights a real 
need for further study to determine whether these proteins act to facilitate Bax’s role in 
mitochondrial bioenergetics. 
A recent proteome-wide quantification of proteins analysis conducted in Bax-containing 
and Bax-deficient HCT-116 cells shows that a number of mitochondrial proteins, like VDAC, 
were found to be down regulated significantly upon loss of Bax [48].  Two enzymes essential for 
glucose metabolism and ATP production were also decreased in Bax deficient cells: Glucose-6-
phosphate isomerase was reduced over 10-fold and citrate synthase was reduced over 7-fold.  
Consistent with this, our results showed reduced citrate synthase activity in Bax
-/-
 HCT-116 cells.  
Loss of critical metabolic components exacerbates the inability of Bax deficient cells to produce 
energy from glucose.  However, the impairment of citrate synthase activity in the Bax
-/-
 cells was 
restored by the reintroduction of Bax into these cells with dramatically increased respiration and 
ATP production.  These data strongly supports the concept that Bax plays an important 
homeostatic role in supporting growth and metabolism. 
In conclusion, we have shown that Bax localized to outer and inner mitochondrial 
membranes in non-apoptotic cells and participated in citrate synthase activity, intracellular ATP 
production and oxygen consumption.  Loss of Bax led to impairment of mitochondria respiring 
morphology and oxidative capacity, all of which can be restored by expression of full-length 
Bax.  Bax C-terminal deletion can also restore mitochondrial bioenergetics.  These findings 
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indicate that the constitutive expression of inactive form Bax is associated with mitochondria and 
is necessary for mitochondrial bioenergetics.  
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CHAPTER 3: THE C-TERMINAL α9-HELIX OF BAX IS THE EFFECTOR 
DOMAIN OF APOPTOTIC FUNCTION 
Introduction 
Bax participates in the induction of apoptosis in response to a variety of apoptotic signals 
[1].  Although the precise mechanism responsible for its apoptotic activity remains undefined, 
Bax conformational changes and translocation into the mitochondria are recognized as the key 
events triggering mitochondria-dependent apoptosis.  Once inserted into the mitochondrial 
membrane, Bax undergoes conformational changes, leading to membrane destabilization.  This 
leads to the release of cytochrome c, SMAC/DIABLO, and Htra2/Om from the mitochondrial 
intermembrane space into the cytoplasm where they amplify the caspase cascade, resulting in 
apoptotic cell death.  Although the pro-apoptotic activity of Bax is well-established, how Bax 
translocates to mitochondria and triggers apoptosis remains unclear.  
Recently, specific regions in the C terminus of Bax have been found to be critical in the 
regulation of Bax binding to mitochondria [1, 8, 13, 48].  In some studies, the C-terminus has 
been considered to be required for Bax binding to mitochondria and represents a transmembrane 
domain to facilitate translocation and insertion of Bax to the outer membrane of mitochondria 
[12, 13, 18, 49, 50]. Other reports suggest that the C-terminal anchor is not required for Bax 
translocation during apoptosis [14, 22, 25].  In these latter studies, deletion of the C-terminal 22 
amino acids failed to block recruitment of Bax to mitochondria during apoptosis [22].  Thus, 
whether the C-terminus of Bax is a membrane binding domain or a regulatory domain remains to 
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be analyzed.  Recently, we performed computational-mutagenesis to identify possible structural 
elements of the C-terminal necessary for Bax membrane binding activity.  Based on variations in 
helical packing energy, we predicted that lysines 189/190, in the α9 helix at the C-terminal, may 
be crucial for Bax membrane insertion (Khaled A, unpublished data).  Therefore, the purpose of 
the present study was to determine whether lysines189/190 at the C-terminal helix are the 
structural elements that mediate the binding of Bax to mitochondria and regulate its apoptotic 
activity.  Data presented here demonstrated that the C-terminal α9-helix is the functional domain 
responsible for the apoptotic function of Bax.  Expression of full-length Bax (Bax-FL) led to 
mitochondrial translocation and apoptosis, whereas deletion of the α9 helix resulted in cytosolic 
retention and no apoptosis.  Mutation of the two lysine residues changed localization of Bax to 
mitochondrial membranes.  These results were replicated by attaching the last 20 amino acids of 
the α9 helix of Bax to either GFP or to a regulatory element, a degradation domain (DD).  We 
demonstrated that the α9 helix alone promoted the mitochondrial translocation of either GFP or 
the DD and increased apoptosis.  These results indicated that the C-terminal α9 helix of Bax 
alone is sufficient to promote cell death.   
Materials and Methods 
Cell lines and Reagents 
The Flp-In T-REx-293 cell line (Invitrogen) was derived from 293 human embryonic 
kidney cells and stably expresses the lacZ-Zeocin fusion gene and the Tet repressor.  The 293 
cell line was maintained in D-MEM (high glucose), 10% FBS (tetracycline-reduced), 2 mM L-
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colorectal cancer cell lines [51] (a kind gift from Dr. Bert Vogelstein, John Hopkins 
University) were maintained in McCoy’s 5A media, 10% FBS and 1% Penicillin-Streptomycin 
(McCoy’s complete medium). 
Plasmids, Mutagenesis and Transfection 
PCR-directed mutagenesis of the C-terminus of Bax was performed using HA-tagged 
primer sets (Table 1), with mutations incorporated within the primer sequences.  For inducible 
expression of Bax wild-type (WT) and mutant proteins, we employed the Flp-In T-REx System 
(Invitrogen).  Bax constructs were amplified by PCR from the template, pEGFP-Bax (a gift from 
Dr. Richard Youle, NINDS, NIH), digested with EcoRV and cloned into the plasmid, pcDNA5/ 
FRT/TO, which undergoes recombinase-mediated DNA recombination at the Flp Recombination  
Target (FRT) site when co-expressed with the pOG44 plasmid that constitutively expresses the 
Flp recombinase.  All constructs were confirmed by sequencing. The pOG44 plasmid and the 
pcDNA5/FRT/TO vectors were co-transfected into the Flp-In T-REx 293 cell line, at a ratio of 
9:1, using Fugene transfection reagent (Roche) following manufacturer’s protocol.  Stable Flp-In 
T-REx expression cell lines were then selected for Blasticidin resistance (10μg/ml), Hygromycin 
resistance (100μg/ml) and Zeocin sensitivity (200μg/ml). Bax expression in 293 cells was 
induced by the addition of tetracycline (1μg/ml) and cells were assayed for the mitochondrial 
translocation of Bax by immunoblotting as described below. 
To generate the EGFP fusion C-terminus (amino acids 168-192) of Bax (EGFP-Bax-CT) 
constructs, primers incorporating the C-terminus of Bax (Table 1) were used in a PCR to amplify 
EGFP from the template pEGFP (Clontech), and the PCR insert was cloned into 
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pcDNA5/FRT/TO as previously described. Bax
-/-
HCT-116 cells were transiently transfected and 
cells assayed microscopically for EGFP expression 48 hours later. 
To generate the DD-tagged Bax C-terminus (amino acids 173-192) wild-type (WT) or 
EE, LL, and RR mutations, primers were annealed and ligated into the ProteoTuner vector 
digested by EcoRI and BamHI.  To generate the DD-tagged full-length WT Bax and CT-Bax, 
the PCR product of Bax was digested with XhoI and EcoRI restriction endonucleases and ligated 
into the ProteoTuner vector.  The ProteoTuner IRES2 system also has the marker protein GFP 
downstream to the internal ribosome entry sequence (IRES) and can be translated independently 
of the DD-tagged Bax protein. 
Mitochondrial Translocation Assay and Immunoblotting 
To examine the mitochondrial translocation of Bax, HA-tagged full-length Bax and its 
mutants were transfected into HEK293 cells and expression of Bax was induced by addition of 
1μg/ml tetracycline for 24 hrs.  To further determine the Bax C-terminal mutations on Bax 
mitochondria translocation, EGFP-CT-Bax or Bax-ΔCT was constitutively expressed in Bax
-/-
 
HCT116 cells for 24 hrs.  We also examined whether DD-tagged Bax C-terminal peptide and its 
mutants could affect Bax mitochondria translocation.  DD-tagged FL-Bax and DD-tagged CT-




 HCT-116 cells 
for 24 hrs, then expression of these DD-tagged constructs were induced by the addition of shield 
for 4 hrs.  The cells were then lysed and mitochondrial and cytosolic proteins were isolated using 
a mitochondrial enrichment kit (Pierce) according to the manufactor’s instructions.  The final 
mitochondrial pellet was washed in 1M NaCl (in place of carbonate (pH 11) buffers) to remove 
any proteins peripherally associated with mitochondria.  Mitochondrial and cytosolic protein 
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fractions were loaded on 12-15% SDS-PAGE gels, transferred to PVDF membranes and probed 
with the appropriate primary antibodies.  For detection of HA-tagged Bax, an anti-HA mouse 
monoclonal antibody was used (16B12, Covance).  Anti DD monoclonal antibody (631073, 
Clontech) was used to probe for DD-Bax.  Antibodies for the loading controls and for 
mitochondrial and cytosolic contents were: endogenous Bax (N-20 Santa Cruz), prohibitin (Ab-
2, Fitzgerald) and p38 MAP kinase (MAPK) (C20, Santa Cruz).  A mouse polyclonal antibody 
was used for detection of EGFP (A.v. antibody, Clontech).  Appropriate secondary rabbit or 
mouse antibodies conjugated to horseradish peroxidase (HRP) and enhanced chemiluminescence 
kit (Pierce) was used for visualization following the manufacturer’s protocol.  
Fixed- and Live-Cell Imaging  
To determine whether expression of the C-terminal of Bax mutations affect the apoptotic activity 
of Bax, Bax
-/-
 HCT-116 cells were grown on coverslips coated with 200 μg/ml poly-L-lysine 
(Sigma) and co-transfected with both EGFP and one of the HA-tagged Bax mutant constructs 
using Mirus LT-1 reagent following manufacturer’s protocol.  After 48 hours, apoptotic cell 
death was assessed by loss of EGFP-expressing cells.  Images were acquired using a Nikon 
Eclipse E1000 microscope (10X objective) with a SPOT RT camera. 





HCT-116 cells were cultured for 24 hours on coverslips 
pretreated with laminin.  The DD-Bax C-terminal WT peptide and DD-Bax C-terminal EE, LL, 
RR mutations constructs were transfected into the cells using Mirus LT-1 reagent according 
manufacturer’s protocol.  After 24 hrs, expression of the transfected peptides was induced by the 
36 
 
addition of shield 1 for 4 hrs.  Cells were fixed with 2% w/v formaldehyde/PBS for 15 minutes 
and permeabilized using 0.05% Triton X-100/PBS for 15 minutes.  After washing, cells were 
incubated with primary antibodies HSP60 (H-300, Santa Cruz) and DD monoclonal antibody for 
1 hour at room temperature, followed by incubation with secondary anti-rabbit-Cy3 (81-6115, 
Invitrogen) and anti-mouse-Texas red (715076020, Jackson Immunoresearch) for 30 minutes.  
After the final wash, cells were mounted with gel/mount medium (Mo1, Biomeda) and images 
were acquired with UltraView (PerkinElmer) microscopy with a plan-apochromat 63 X /1.4 oil 
objective.  The scanned images were processed and Pearson’s correlation coefficients determined 
using Velocity Version 5.5 (Perkin Elmer).  Analysis of the images was completed through 





 HCT-116 cells were cultured in 24-well plates (MatTek Corporation) in 
McCoy’s complete medium.  Cells were transfected with the GFP-tagged C-terminal wild type 




 HCT116 cells using the 
TransIT-LT1 transfection reagent (Mirus) according to the manufacturer’s protocol.  After 
transfection for two hours, time-lapse movies were made for 12 hrs using the UltraView 
(PerkinElmer) spinning disc confocal system with AxioObserver.Z1 stand, and a Plan-
Apochromat 10x objective. Snapshots were taken as indicated in the images. 
The constructs of DD-Bax-C-terminal-WT, DD-Bax-CT-EE, DD-Bax-CT-LL, DD-Bax-
CT-RR were delivered as mentioned above for 48 hours.  Cells were incubated with 1nM 
MitoTracker Red 580 in McCoy’s complete media for 30 minutes at 37 °C prior to imaging.  
Time-lapse movies were recorded for 5 hrs using the UltraView spinning disc confocal system 
(PerkinElmer) with AxioObserver.Z1 (Carl Zeiss) stand equipped with a Plan-Apochromat 63x 
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Oil DIC objective, in a humidity and temperature-controlled chamber (LiveCell). Z-stack 
projections of the scanned images were generated within the imaging program, Volocity Version 
5.5 (PerkinElmer). Post-acquisition snapshots were taken from time-lapse movies.at 0, 3 and 
5hrs. 





 HCT-116 cells were plated in 6-well plates, and cells transfected with 
DD-Bax C-terminal WT, EE, LL, or RR mutants  for 24 hrs, followed by treatment with Shield 1 
to induce peptide expression for an additional 24 hrs.  Cells were collected at a final 
concentration of 1 x 10
6 
cells/ml in HBSS.  Cells were then stained using the Violet Ratiometric 
Membrane Asymmetry Probe/Dead Cell Apoptosis Kit (A35137, Invitrogen) according the 
manufacturer’s protocol by adding F2N12S solution and SYTOX® AADvanced™ dead cell 
stain solution to each sample.  Analytes were incubated at room temperature for 5 minutes, and 
then analyzed using the BD FACSAria II flow cytometer. F2N12S was visualized with a laser 
source at 405nm and emissions collected at 530nm and 585nm, and excitation of SYTOX® 
AADvanced™ visualized at 488nm and emissions collected at 695nm. 
Statistical Analysis 
Data were presented as mean ± SD. Statistical analysis was determined using Prism for 





The C-terminal α9 helix is critical for Bax intracellular localization and apoptotic activity  
To verify our predictions derived from our computational studies, we performed a series 
of mutagenesis experiments targeting the C-terminal of Bax, as summarized in Table 2.  We 
generated wild-type (WT) and N- or C-terminal deleted Bax mutants as well as the C-terminal 
Lys189/190 mutants.  The inducible expression of Bax mutants in 293 cells, upon addition of 
tetracycline, was examined by immunoblot. In this cell model system, the inducible low 
expression of Bax in these cells did not cause apoptosis.  p38 MAPK and prohibitin were used as 
indicators for cytosolic and mitochondrial content, respectively.  Expression of WT Bax was 
found both in cytosolic and mitochondrial extracts.  The N-terminal deleted Bax lacking residues 
1-19 (Bax-ΔNT), was localized primarily to mitochondria, while the C-terminal deleted Bax 
lacking residues 173-192 (Bax-ΔCT), was retained in the cytosol (Fig. 5, Table 2).  To examine 
whether expression of these Bax constructs would induce apoptosis, we constitutively co-
expressed WT Bax or the deletion mutants along with GFP in a Bax deficient cell line (Bax
-/- 
HCT116) [51].  As shown in Figure 6, like Bax-ΔNT, expression of WT Bax induced apoptosis 
in Bax
-/- 
HCT116 cells, as evidenced by the loss of GFP
+ 
cells, whereas Bax-ΔCT remained 
cytosolic and did not induce apoptosis, as evidences by the presence of GFP
+ 
cells.  These results 
show that an intact C-terminus of Bax causes apoptosis, while the N-terminus promotes cytosolic 
retention.  
Substitution of Lys189 and/or Lys190 with negatively charged residues, Asp or Glu, 
resulted in the cytosolic retention of Bax (Bax-DD, Bax-EE, and Bax-EK) in 293 cells, and no 
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apoptosis was observed in BAX
-/- 
HCT116 cells (Table 2, Figs. 5 and 6).  Whereas, substitution 
of Lys189 and/or Lys190 with another positively charged residue, Arg (Bax-RR) led to 
mitochondrial localization and apoptosis (Table 2, Figs. 5 and 6).  Substitution of Lys 189 and 
Lys190 with a polar amino acid, like Gln (Bax-QQ), led to more Bax in the cytosol and less cell 
death, when compared WTBax and Bax-RR, but more mitochondrial Bax and cell death was 
observed when compared to Bax-ΔCT and Bax-EE (Table 2, Figs. 5and 6).  Substitution of 
Lys189 and/or Lys190 with the hydrophobic residue leucine (Bax-LL) resulted in mitochondrial 
binding and apoptosis (Figs. 5 and 6, Table 2).  Loss of Lys189 (Bax-EK) also rendered Bax to 
be mainly cytosolic, which was not observed by loss of Lys190 (Bax-KMGK) (Figs. 5 and 6, 
Table 2).  These data suggest that Lys 189/190 was essential for both Bax binding to 
mitochondria and its apoptotic activity.  
The C- terminus Lys 189/190 of Bax is involved in Bax binding to mitochondria 
To determine whether the C-terminus Lys 189/190 is critical for Bax binding to 
mitochondria, we attached the C-terminal α9 helix of Bax (CT) (amino acids 168-192) to EGFP 
(EGFP-CT) and examined the subcellular localization in Bax
-/-
 HCT-116 cells. Moreover, mutant 
C-terminal constructs, CT-EE and CT-LL, were also attached EGFP for evaluation.  The 
constructs were constitutively expressed in Bax
-/- 
HCT-116 cells.  After 24 hours, Bax C-
terminal tagged EGFP was assayed by immunoblotting with an anti-EGFP antibody in both 
mitochondrial and cytosolic lysates.  As shown in Figure 7, a heavy band of EGFP was observed 
in cytosolic lysates but not in mitochondrial lysates.  Both EGFP-CT-WT) and EGFP-CT-LL 
expression displayed translocation from cytosol to mitochondria, as evidenced by the increased 
aggregates of EGFP in the mitochondrial extracts. EGFP-CT-EE was located in the cytosolic but 
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not in the mitochondrial fractions, as evidenced by the decreased aggregates of EGFP in the 
mitochondrial extracts.  These data further confirmed that Lys 189/190 in the C-terminal of Bax 
are involved in Bax binding to mitochondria.   
The C- terminus Lys 189/190 of Bax is critical for Bax apoptotic activity   
Since Lys 189/190 mutants displayed different intracellular localization (Fig. 7), we 
determined whether these mutants altered the apoptotic process in the presence and absence of 
endogenous Bax using Bax
+/+
 HCT-116 and Bax
-/- 
HCT-116 cells.  Apoptosis was detected by 
live cell imaging to examine any morphological changes over time after transfection with EGFP-
tagged Bax C-terminal and its mutants.  As shown in Figure 8, expression of EGFP-CT-WT in 
Bax
+/+
 HCT-116 cells quickly caused apoptotic cell death, whereas expression of both EGFP-
CT-EE and EGFP-CT-LL did not induce apoptosis within the same time period.  However, 
expression of EGFP-CT-WT in Bax
-/-
 HCT-116 cell, or either EGFP-tagged CT-EE, or LL 
mutants, did not cause cell death within the same time period.  These results suggest that Lys 
189/190 is crucial for Bax apoptotic activity and also indicates that the apoptotic activity of 
EGFP-tagged CT-WT might be correlated and depend upon the levels of endogenous Bax.  
Expression of the C-terminal α9 helix of Bax induces the translocation of Bax to 
mitochondria  
To further determine whether expression of the C-terminal α9 helix of Bax induces the 
translocation of Bax to mitochondria, we examined the effects of induction of DD-tagged full-
length Bax (DD-FL-Bax) and DD-tagged C-terminal α9 helix (amino acids 173-192) (DD-CT-
Bax) WT and EE, LL, RR mutations.  Mitochondrial translocation of the DD-CT Bax constructs 
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was examined in HCT-116 cells. To induce expression, Shield 1 was added for after to cells that 
had been transfected with constructs for 24 hours. Induction time was 4 hours. Both the cytosolic 
and mitochondrial proteins were isolated from non-apoptotic HCT116 cells, and the expression 
of DD-tagged Bax peptides and endogenous Bax were determined by immunoblots with either 
anti-DD or anti-Bax antibodies.  As shown in Figure 9, most of DD-tagged full-length Bax was 
found in cytosolic extracts, and a substantial fraction of DD-FL-Bax was also found in 
mitochondria extracts.  Expression of DD-CT-WT Bax peptides or DD-tagged mutant peptides 
(EE, LL and RR) was observed all in the mitochondrial extracts; only DD-tagged LL was found 
a very faint band in the cytosolic extracts.  More interestingly, expression of DD-tagged C-
terminal Bax activated endogenous Bax, which was observed by translocation into mitochondria.  
These results were further confirmed by immunofluorescence, double-staining with anti-DD and 
anti-HSP60 (mitochondrial content) antibodies (Fig.10A).  Expression of DD-CT-WT and 
mutants (EE, LL and RR) localized to mitochondria as evidenced by double-positive staining.  





HCT-116 cells (Fig.10B).  These data suggest that expression of C-
terminal α9 helix of Bax alone can bind to mitochondria. 
Expression of the C-terminal α9 helix of Bax induces apoptotic cell death 
To determine whether the C-terminal α9 helix of Bax could mimic the apoptotic activity 
of the full-length Bax, expression of DD-tagged Bax-FL, the C-terminal α9 helix of Bax and its 




HCT-116 cells as described in Methods. Cells 
were transfected for 24 hours.  To image mitochondria, the cells were incubated 30 minutes with 
1nM MitoTracker Red 580.  Cells were imaged before adding   shield 1 and 5 hours after adding 
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shield 1.   As shown in Figure 11, expression of DD-CT-WT caused apoptotic cell death in both 
Bax
+/+
 HCT-116 and Bax
-/-
 HCT-116 cells within 5 hours.  However, expression of DD-tagged 





116 cells within the same time period.  The apoptotic activity of DD-tagged CT-WT was further 
examined by flow cytometry analysis.  Representative cytometric analytical data are shown in 
Figure 11 and Table 3. Cells were examined 24 hours after addition shield 1. Parameters 
assessed were early apoptotic indicators (DNA fragmentation and membrane instability).  From 
previous data (Figure 11), cells expressing  high levels of DD-tagged WT peptide died within 5 
hours after induction in Bax
+/+
 cells.  Whereas 24 hours after induction, cells, mostly expressing  
low levels of DD-tagged CT-WT peptide, showed less DNA fragmentation and membrane 
destabilization. Cells expressing heterogeneous levels of DD-tagged EE showed less DNA 
fragmentation and membrane instability. Cells expressing DD-tagged LL showed increased 
DNA fragmentation but less membrane destabilization. Cells expressing heterogeneous levels of 
DD-tagged RR showed both increased DNA fragmentation and membrane destabilization.  
These data suggest that DD-tagged CT-WT has significant cell toxicity and kills cells quickly, 
while DD-tagged RR has the potential to kill cells but may take longer. DD-tagged LL and EE 
displayed the least cell toxicity.  These results showed the possible cytotoxic effects of Bax 
binding to mitochondria, as evidenced by immunoblots shown in Figure 9.  Taken together, these 
data suggest that the C-terminal α9 helix of Bax may activate endogenous Bax, thereby 
enhancing Bax apoptotic activity in Bax
+/+ 
HCT-116 cells, and that Lys 189/190 is instrumental 
for the apoptotic activity of the C-terminal α9 helix of Bax.  
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Expression of the C-terminal of Bax on ATP production in HCT-116 cells 
Since we had shown that expression of the full-length Bax can restore ATP production in 
Bax
-/-
 HCT-116 cells, we examined whether the C-terminal α9 helix of Bax could mimic the 
activity of the full-length Bax on ATP production.  After transfection of DD-tagged C-terminal 
α9 helix of Bax constructs for 24 hours, expression of DD-CT-WT of Bax peptides was induced 




 HCT-116 cells.  The intracellular ATP 
production was examined as described in the Methods in Chapter 2.  As shown in Figure 13, the 
basal levels of ATP in non-transfected Bax
+/+
 controls is higher than that in the Bax
-/-
 controls.  
Expression of the DD-tagged C-terminal α9 helix of Bax (WT or mutants) had no significant 
effects on ATP production in both Bax
+/+
 HCT-116 cells and Bax
-/-
 HCT-116 cells.  These 
results suggest that the C-terminal α9 helix of Bax may be not involved in the regulation of 





Figure 5. Mutation of Lys 189/190 at C-terminal of Bax alters intracellular localization.  
Mitochondrial translocation of HA-tagged Bax mutants was examined by western blot.  Bax was 
inducibly expressed in 293 cells using the Flp-In T-Rex expression system.  After 24 hours of 
induction with tetracycline, cells were lysed and mitochondrial and cytosolic lysates prepared.  
Expression of induced HA-tagged Bax was assayed by immunoblotting with an anti-HA 
antibody.  As controls for loading and subcellular fractionation, p38 MAPK was blotted for 
cytosolic content and Prohibitin was blotted for mitochondrial content.  HA-tagged Bax-KK 






Figure 6.  Mutation of Lys 189/190 at C-terminus of Bax alters apoptotic activity of Bax. 
Apoptosis was assessed by loss of EGFP expressing cells.  HA-tagged Bax mutants were 
transiently co-expressed with EGFP in Bax
-/- 
HCT116 cells.  After 48 hours, HCT116 cells were 
microscopically observed for loss of EGFP+ cells.  Images were obtained using a Nikon Eclipse 



















Figure 7. EGFP tagged C- terminus Lys 189/190 mutation of Bax alters intracellular localization. 
Mitochondrial translocation of EGFP-tagged Bax C-terminus mutants was examined by western 
blot.  Bax was inducibly expressed in Bax
-/-
HCT116 cells using the Flp-In T-Rex expression 
system.  After 24 hours of induction with tetracycline, cells were lysed and mitochondrial and 
cytosolic lysates prepared.  Induced EGFP-tagged Bax peptides were probed with an anti-GFP 









Figure 8. GFP tagged C-terminal peptide of Bax, but not mutant peptides, induced cell death in 
HCT-116 cells. 
Cells were transfected with the GFP-tagged C-terminal wild type (KK), EE and LL mutants of 




 HCT116 cells using the TransIT-LT1 transfection 
reagent (Mirus) according to the manufacturer’s protocol.  Time-lapse movies were made by the 
UltraView spinning disc confocal system with AxioObserver.Z1 stand, and a Plan-Apochromat 






Figure 9. Intracellular localization of DD-tagged full-length and DD-tagged C-terminus Lys 
189/190 mutants. 
The intracellular localization of DD-tagged Bax full-length (FL-Bax) and C-terminus mutants 
was examined by western blot.  Bax was inducibly expressed in Bax
+/+
HCT-116 cells by adding 
the ligand Shield 1. After 4 hours of induction, cells were lysed and mitochondrial and cytosolic 
lysates were extracted.  Expression of induced DD-tagged Bax peptides was assayed by 
immunoblotting with an anti-DD antibody.  Endogenous Bax were probed with anti-Bax 
antibody.  p38 MAPK and prohibitin were probed as loading controls for cytosolic and 





Figure 10. Detection of intracellular localization of DD-tagged C-terminus Lys 189/190 mutants 





 HCT-116 cells were cultured for 24 hours.  The DD-tagged Bax C-terminal WT 
peptide and DD-tagged Bax C-terminal EE, LL, RR mutants constructs were transfected into the 
cells for 24 hours, followed by treatment with shield 1 for 4 hours.  Cells were fixed and double-
stained with primary antibodies for HSP60 and DD, followed by incubated with secondary anti-
rabbit-Cy3 and anti-mouse-Texas red as described in methods.  Representative images are shown 
in (A).  The bar graphs (B) indicated the quantitative assay of colocalization of DD-tagged 
peptides to mitochondria.  The measurements are represented by three samples. Statistical 
analysis was performed with ANOVA and there is no statistically significant difference. 






Figure 11. Expression of DD-tagged Bax C-terminal peptides induced cell death in HCT-116 
cells. 





 HCT-116 cells using the TransIT-LT1 transfection reagent at described in 
the methods.  After adding shield 1 to induce the Bax peptide expression, the time-lapse movies 
were acquired with the UltraView spinning disc confocal system over 5 hours.  Snapshots were 






Figure 12. Detection of cell death by flow cytometry. 
DD-tagged Bax C- terminus wild type (DD-CT-KK) ant its mutants (DD-CT-EE, DD-CT-LL 
and DD-CT-RR) were transfected into the Bax
+/+
 HCT-116 cells using the TransIT-LT1 
transfection reagent at described in the Methods.  After induction with shield 1 for 24 hours, cells 
(1x10
6
) were harvested and stained with F2N12S and SYTOX® AADvanced™ solutions as 
described in methods.  Samples were analyzed on BD FACSAria II flow cytometer.  Data are 















 HCT-116 cells were transiently transfected with DD-tagged Bax-CT-WT for 24 
hrs, then cells were treated with shield 1 for 0, 2, 4, 6, 8 hours.  Changes in ATP levels were 
measured as described in methods.  There was no statistically significant difference in ATP 




















As an important pro-apoptotic protein, Bax is involved in the pathology of a number of 
diseases and is increasingly considered as a potential therapeutic target.  Abounding evidence has 
demonstrated that translocation of Bax to the mitochondria, permeabilization of the 
mitochondrial outer membrane and release of cytochrome c are key events in apoptosis [1-3].  
Bax is a member of the BCL-2 family of apoptotic modulators that exists either in a soluble 
cytoplasmic form or a membrane-bound form.  Today, growing evidence indicates that upon 
apoptotic stimuli, Bax undergoes a conformational change, exposing its C-terminal α9 helix, and 
translocates to mitochondria, leading to apoptosis [8, 18-20].  It is unknown, however, whether 
the α9 helix of Bax is a membrane binding domain or a regulatory domain.  In our previous 
computational mutagenesis studies, we predicted that Lys 189/190 at the C-terminal α9 helix of 
Bax may play a critical role in the regulation of mitochondrial membrane binding activity of Bax 
in response to apoptotic stimuli (Khaled A, unpublished data).  In the present study, using a 
mutagenesis strategy we identified that positively charged lysines 189/190, located at the distal 
end of the C-terminal α9 helix of Bax, are critical for the apoptotic activity of Bax, and these two 
lysines might define how Bax interacts with mitochondrial membranes.  We showed that 
expression of full-length Bax (Bax-FL) led to mitochondrial translocation and apoptosis, whereas 
deletion of the C-terminal α9 helix resulted in cytosolic retention and no apoptosis.  Mutation of 
the two lysine residues changed how Bax bound to mitochondrial membranes.  We replicated the 
results achieved with full-length Bax by attaching the α9 helix of Bax to EGFP or to a regulatory 
element, a degradation domain (DD), and induced apoptosis upon expression in cells, whereas 
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these effects were impaired by mutation of Lys 189/190.  These results indicated that the two 
lysines in the α9 helix are critical for the apoptotic activity of Bax. 
Bax translocation from the cytosol to the mitochondria is a critical event of apoptosis.  
Currently, Bax activation by direct interaction with BH3-proteins has been suggested [50].  
However, this working model cannot explain how Bax moves to mitochondria in cells from mice 
deficient in BIM, BAD or PUMA, suggesting that translocation of Bax can occur independently 
of such BH3-only proteins [53].  Thus, it was recently suggested that the conformational change 
of Bax occurs in the cytosol leading to release of the C-terminal α9 helix from the hydrophobic 
grove, thereby exposing the previously hidden BH3 domain and then Bax anchors into the OMM 
through its N-terminus [14] or its C-terminus [19].  Our recent studies showed that the increase 
in intercellular pH could induce a conformation change in Bax, resulting in the C-terminal being 
exposed, leading to Bax mitochondria translocation [21].  In non-apoptotic cells, the C-terminal 
helix 9 occupies the hydrophobic groove of Bax.  It is possible that the conformational change 
that occurs upon an apoptotic stimulus may expose the membrane binding domains, since the C-
terminus has been proposed to mediate the mitochondrial insertion of Bax.  In contrast, studies 
demonstrated that the N-terminal α1 helix domain, not the C-terminal, is essential for Bax 
insertion and function [14, 22, 54].  To understanding the role of the C-terminal of Bax, mutation 
of the C-terminal (Bax-ΔCT) was performed and we found that expression of Bax-ΔCT retained 
Bax in the cytosol and abolished apoptosis in Bax
-/-
 HCT-116 cells.  However, mutation of the 
N-terminal (Bax-ΔNT) caused Bax to move to mitochondria and cell death.  These data suggest 
that the α9 helix plays an essential role in the translocation of Bax to mitochondria.  The crucial 
role of α9 helix was investigated by analyzing different substitutions at Lys 189/190, the positive 
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charged residues in α9 helix.  Data presented here clearly demonstrated that the C-terminal α9 
helix can mediate insertion of Bax into mitochondria.  We also identified Lys 189/190 as critical 
for the apoptotic activity of Bax. We replicated the results achieved with full-length Bax by 
attaching the α9 helix of Bax to EGFP or to a regulatory element, a degradation domain (DD), 
and induced the translocation of Bax to mitochondria and induced apoptosis upon expression in 
cells.  Our conclusions are based on results derived from computational structural studies, 
targeted mutagenesis studies, and analysis through live cell imaging, flow cytometry, and 
immunoblotting.    
Work done by others have shown that the modification of C-terminal residues by 
phosphorylation could be a means to regulate the mitochondrial translocation of Bax.  For 
example mutation of serine 184 in the full length protein [56] or a C-terminal peptide [57] altered 
the localization and membrane-binding functions of Bax protein or peptide.  Substitution of 
Ser184 with Asp, Gln or Lys leads to a protein exclusively cytosolic, whereas the deletion of 
Ser184 or substitution with Val or Ala causes to a protein exclusively localized to the 
mitochondria [58].  Mutation of threonine likewise did the same [55], suggesting that the C-
terminus of Bax was a regulatory domain.  We found that mutation of the two lysines 
significantly affected the apoptotic activity of the C-terminal of Bax.  Mutation of these two 
lysines altered Bax intracellular localization. Expression of the C-terminal Bax mutants may 
activate the endogenous Bax by  moving it to mitochondria.  Recently, it was reported that the 
Bax C-terminus was essential for Bax translocation to mitochondria but was not the only binding 
signal [59].  Therefore, it will be interesting to examine how the C-terminal  mutants affect the 
intracellular localization of endogenous Bax. 
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In summary, our results suggest that the C-terminal α9 helix of Bax serves as a 
mitochondrial membrane binding domain and that Lys 189/190 are critical for the apoptotic 
activity of Bax.  This study also suggests that expression of the C-terminal α9 helix is sufficient 
to induce apoptotic cell death, indicating the C-terminal α9 helix may be developed as a novel 




CHAPTER 4: CONCLUSIONS 
Apoptosis is essential for tissue development and homeostasis, and is involved in many 
disease pathologies.  The Bcl-2 family of proteins is a major regulator of apoptosis and includes 
both pro- and anti-apoptotic proteins.  The balance between these proteins defines whether a cell 
will live or die.  Bax is a well-known pro-apoptotic Bcl-2 family protein which participates in the 
induction of apoptosis in response to a variety of apoptotic signals.  Mostly Bax resides in the 
cytoplasm of non-apoptotic cells, and a minor fraction of Bax is associated with the 
mitochondrial membrane.  Multiple mechanisms have been suggested to explain how Bax 
induces apoptosis. The translocation of Bax to mitochondria is considered as a principal trigger 
of apoptosis, although how Bax translocates to mitochondria remains unclear.  Recently, it has 
been shown that Bax can affect mitochondrial reactive oxygen species (ROS) production in non-
apoptotic neurons, suggesting that Bax localizes to and uses mitochondria as its major site of 
action, and has dual function in regulation of cell fate. 
The results presented here demonstrate that Bax has a dual property of action: (1) 
regulation of mitochondrial bioenergetics in non-apoptotic cells, and (2) triggering apoptosis by 
translocation to mitochondria via its C-terminal α9 helix.  Our results, however, suggest that the 
C-terminal α9 helix domain is not involve in or regulates mitochondrial bioenergetics, and that 
the Lys189/190 at the C-terminal α9 helix is the structural element responsible for the 
mitochondrial membrane binding activity of Bax.  We further demonstrate that the C-terminal α9 
helix can mimic the function of the full-length Bax, binding to mitochondrial membranes and 
inducing apoptosis. These results suggest two possible mechanisms to explain the apoptotic 
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activity of the C-terminal peptides.  One mechanism could be that the peptides directly bind to 
mitochondria, disrupt the membrane and cause the release of cytochrome C.  Alternatively, the 
C-terminal peptides could bind to and activate cytoplasmic Bax, which translocates to the 
mitochondria and causes the release of cytochrome C.  Thus, development of a novel agent based 
on the C-terminal of Bax may overcome resistance to cancer chemotherapy and could be used as 
therapeutic strategy for treatment of cancer.  On the other hand, Bax C-terminal mutate peptides 
(like Bax-CT-EE) may counteract apoptosis and protect cells from damage that leads to 
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